Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
43 hedge funds and large institutions have $7.55M invested in Argos Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 12 closing their positions.
5,844% more call options, than puts
Call options by funds: $2.44M | Put options by funds: $41K
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 52 → 43 (-9)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
93% less capital invested
Capital invested by funds: $102M → $7.55M (-$94.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.51M |
| 2 |
Renaissance Technologies
New York
|
+$696K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$402K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$350K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$9.71M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.13M |
| 3 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$845K |
| 4 |
Millennium Management
New York
|
-$701K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$595K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
V
51
Veritable
Wilmington,
Delaware
| – | -$51K | -520 | Closed |
|
|
AIM
52
Acrospire Investment Management
Chicago,
Illinois
| – | -$9K | -90 | Closed |
|
|
ECM
53
Exchange Capital Management
Ann Arbor,
Michigan
| – | -$5K | -50 | Closed |
|
54
Barclays
London,
United Kingdom
| – | +$1.27K | +20 | +111% |
|
|
MAM
55
Meeder Asset Management
Dublin,
Ohio
| – | +$1.27K | +20 | New |
|
ARGS Hedge Fund Activity: Q1 2017 in Review
43 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q1 2017, worth a combined $7.55M — down 93% from $102M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ARGS and 8 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 16 added.
The largest buyer was BlackRock, adding an estimated $2.51M. The largest seller was Wasatch Advisors, cutting an estimated $9.71M.
- 43 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q1 2017, down from 52 in Q4 2016.
- Funds reported $7.55M of Argos Therapeutics, Inc. stock for Q1 2017, down 93% quarter-over-quarter.
- 8 funds opened new Argos Therapeutics, Inc. positions in Q1 2017 and 12 closed out, a net change of -4 holders.
- The largest Argos Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $2.51M added.
- The largest Argos Therapeutics, Inc. seller in Q1 2017 was Wasatch Advisors, an estimated $9.71M sold.
Based on aggregated 13F filings for Q1 2017.